Bullboard - Stock Discussion Forum Lipocine Inc LPCN

Healthcare Biotechnology

Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products for Central Nervous System (CNS) disorders. Its clinical development candidates include: LPCN 1154, oral brexanolone, for treatment of postpartum depression, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor... see more

Add To Watchlist

NDAQ:LPCN - Post Discussion

Lipocine Inc > FDA Grants Fast Track Designation to Lipocine for LPCN 1148

View:

Post by whytestocks on Dec 17, 2024 2:00pm

FDA Grants Fast Track Designation to Lipocine for LPCN 1148

NEWS: $LPCN FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated CirrhosisFDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis PR Newswire SALT LAKE CITY , Dec. 17, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its ...LPCN - FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis